Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals — Technical Presentation (November 2021)

14 slides from Centessa Pharmaceuticals's technical presentation, Nov 1, 2021

  1. Slide 1: Update for ZF874 Phase 1 Part B

    Update for ZF874 Phase 1 Part B November 1, 2021

  2. Slide 2: Forward-looking statements disclaimer

    This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1

  3. Slide 3: ZF874 Phase 1 Part B interim results: Today's speakers

    ZF874 Phase 1 Part B interim results 3 TODAY’S SPEAKERS GREG WEINHOFF, MD MBA Chief Financial Officer SAURABH SAHA, MD PhD Chief Executive Officer ANTOINE YVER, MD MSc Chief Medical Officer AVAILABLE FOR Q&A JIM HUNTINGTON, PhD Co-founder & Chief Executive Officer of Z Factor DAVID GRAINGER, PhD Co-

  4. Slide 4: First demonstration pharmacological chaperone may achieve >11 µM functional A1AT in PiZZ

    First demonstration that a pharmacological chaperone has the potential to achieve levels greater than 11 µM of functional A1AT in PiZZ subjects • ZF874’s potential to increase functional levels of A1AT to levels >11 µM in individuals with PiZZ genotype is consistent with data from two PiMZ subjects

  5. Slide 5: Introduction to ZF874 – Folding corrector of Z-A1AT

    Introduction to ZF874 – Folding corrector of Z-A1AT 5 Abbreviations: Z-A1AT = alpha-1 antitrypsin with the Z mutation; M-A1AT = wild-type alpha-1 antitrypsin • Small molecule folding corrector of the Z variant of A1AT (Z-A1AT). Catalytic, non-covalent and orally bioavailable • Insights from a propri

  6. Slide 6: Liver pathology is a key feature of A1AT deficiency

    Liver pathology is a key feature of A1AT deficiency Preclinical data shows ZF874 clears polymer and reduces fibrosis 6 ZF874-treated 54 mpk/day (HED 7 mpk/day) Vehicle Z-A1AT polymer (PAS-D staining) Fibrosis (Sirius Red staining) Liver histology from 84-day treatment of mice expressing human Z-A1AT

  7. Slide 7: Schematic of Phase 1 clinical trial for ZF874

    Schematic of Phase 1 clinical trial for ZF874 7 Part A (completed, n=54) SAD Healthy Volunteers Part B (ongoing, n=3) 28-day repeat dosing in PiXZ Demographics First 3 subjects in Part B Subj. Treatment Age Sex Genotype Baseline A1AT* 2001 15 mpk BID (1.6 g BID) 47 M MZ 17.6 µM 2002 Placebo (N/A) 23

  8. Slide 8: A1AT levels for different genotypes and conceptual target

    A1AT levels for different genotypes and conceptual target for an effective folding corrector 8 * Median level from Donato et al. 95% confidence intervals shown. † M level estimated as half of MM and Z level estimated as half of ZZ Source: A1AT levels - Donato et al. “Reference and Interpretive Range

  9. Slide 9: Change in A1AT functional activity for three PiMZ subjects

    Change in A1AT functional activity for three PiMZ subjects dosed with placebo or ZF874 15 mpk BID 9 * Activity level equivalent to molar amount of M A1AT reference standard. Baseline for each subject = average of Pre-Screen , Day -1, and Day 1 Pre-Dose values for each subject † Trapezoidal AUC for t

  10. Slide 10: Liver signal in one PiMZ subject with highest exposure in Part B

    Liver signal in one PiMZ subject with highest exposure in Part B 0 100 200 300 400 500 600 700 -21 -14 -7 0 7 14 21 28 35 42 49 56 63 70 10 Time after 1st dose (days) ALT (IU/L) Treatment period ULN ♂ (70 IU/L) Subject 2002 ♂ Placebo Subject 2003 ♀ AUC0-12hr 181 µg·hr/ml Subject 2001 ♂ AUC0-12hr 350

  11. Slide 11: Adverse Events for subjects in Part B

    Adverse Events for subjects in Part B Subject 2001 (ZF874) – Moderate AE of elevated AST/ALT - possibly drug related – Mild AEs of splenomegaly, headache and diarrhea - unlikely drug related Subject 2002 (placebo) – Mild AE of drowsiness - possibly drug related Subject 2003 (ZF874) – Mild AEs of hea

  12. Slide 12: Next steps for ongoing Phase 1: Accelerate recruitment to establish Phase 2 dose

    Next steps for ongoing Phase 1: Accelerate recruitment to establish Phase 2 dose Updates will be provided as the study progresses to PiZZ subjects • Additional clinical trial sites ― 4 more U.K. sites expected to open this month ― Expansion to the E.U. underway. Includes a site in Ireland with a lar

  13. Slide 13: Commitment to a new global Phase 2 study expected to launch in Q2 2022

    Commitment to a new global Phase 2 study expected to launch in Q2 2022 6-month Phase 2 allows assessment of both serum A1AT levels over time and liver clearance • Two phases ― Run-in. Additional duration and doses to complement ongoing Phase 1 ― Six-month portion. Gated by chronic animal tox availab

  14. Slide 14: Recap: First demonstration of >11 µM functional A1AT potential in PiZZ subjects

    14 Recap: First demonstration that a pharmacological chaperone has the potential to achieve greater than 11 µM levels of functional A1AT in PiZZ subjects • ZF874’s potential to increase functional levels of A1AT to levels >11 µM in individuals with PiZZ genotype is consistent with data from two PiMZ

Centessa Pharmaceuticals — Technical Presentation (November 2021) on 6ix